Brown Advisory US Mid-Cap Growth Fund Euro Class B Acc
WKN A2PHD2 | ISIN IE00BYW8RC09 | Fonds
Aktuelle Entwicklung
Konditionen für Handel via KAG
| Transaktionsentgelt | 5,00 % |
| Managementgebühr | 0,75 % |
| Annahmeschluss | - |
Fondsprofil
| Fondstyp | Aktienfonds |
| Branche | Branchenmix |
| Ursprungsland | Irland |
| KESt-Meldefonds | - |
| Auflagedatum | 03.01.2020 |
| Fondsvolumen | 227,43 Mio. EUR |
| UCITS | Ja |
| Sparplan | Nein |
Performance
| Zeitraum | vor AGA | nach max. AGA |
|---|---|---|
| 1 Jahr | -7,48 % | - |
| 3 Jahre p.a. | +10,29 % | - |
| 5 Jahre p.a. | +3,10 % | - |
52W Hoch:
16,6100 EUR
16,6100 EUR
52W Tief:
11,8200 EUR
11,8200 EUR
Größte Positionen
| West Pharmaceutic.Services Inc | 3,79 % |
| CARDINAL HEALTH INC. | 3,59 % |
| Hilton Worldwide Holdings Inc. | 3,47 % |
| CoStar Group Inc. | 3,24 % |
| Sonstiges | 85,91 % |
Fonds Prospekte
| 2025 Basisinformationsblatt (16.09.25) |
Fondsstrategie
The objective of the Fund is to achieve capital appreciation by investing primarily in U.S. equities.
The Fund invests at least 80% of its net assets in equity securities of mid-cap U.S. companies. The Fund seeks to invest primarily in mid-size companies with above average growth prospects and which are listed or traded on the US markets and exchanges listed in Appendix I of the Prospectus. The Investment Manager has determined that the Fund is an Article 8 financial product for sustainability-related disclosures ("SFDR").
Fondsmanager: Chris Berrier, George Sakellaris
Notizen
Loggen Sie sich in Ihren Markets plus Account ein um schnell und einfach persönliche Notizen zu Wertpapiere zu erfassen.